The AssistMS programme is a collaboration between icometrix, Queen Mary University of London (QMUL), the University of Nottingham, Barts Health and Nottingham University Hospitals Trusts. It will investigate the impact of AI applied to MRI on the decision-making, clinical outcomes and health economics in the care of people with multiple sclerosis (MS).
The programme will focus on the reporting of MRIs, which are used to assess whether disease-modifying treatments are working or not. Typically, these can be time-consuming and tiring, meaning they are prone to human error.
icobrain ms, the software tested in AssistMS, works to detect and highlight subtle changes on MRI brain scans and then provides summary reports. By using AI to analyse the brain scans, neurologists will have access to a more accurate idea of how patients’ MS is progressing. This allows them to make the best possible treatment decisions for individuals.
During the AssistMS project, clinicians will perform their assessments both with and without the support of icobrain ms. The accuracy and consistency of the AI tool will be studied using around 1,300 MS patients in east London and Nottingham.
It will also investigate the impact of the technology on clinical decisions, and explore the economic value of it.
The project will start in the coming months and will run for three years.
Click here to read the original news story.